Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice

BACKGROUND: Obesity and comorbidities onset encompass gut dysbiosis, altered intestinal permeability, and endotoxemia. Treatments that target gut dysbiosis can cope with obesity and nonalcoholic fatty liver disease (NAFLD) management. Peroxisome proliferator-activated receptor (PPAR)-alpha activatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Veiga, Flavia Maria, Miranda, Carolline Santos, Vasques-Monteiro, Isabela Macedo Lopes, Souza-Tavares, Henrique, Martins, Fabiane Ferreira, Daleprane, Julio Beltrame, Souza-Mello, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099201/
https://www.ncbi.nlm.nih.gov/pubmed/35633911
http://dx.doi.org/10.3748/wjg.v28.i17.1814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099201/
https://www.ncbi.nlm.nih.gov/pubmed/35633911
http://dx.doi.org/10.3748/wjg.v28.i17.1814

Ejemplares similares